Highlights

  • A2M fell 2.717% to A$9.31 on April 1, 2026, despite the company reporting 1H26 revenue up 18.8% to NZ$993.5 million, EBITDA up 18.4% to NZ$155.0 million, NPAT up 9.4% to NZ$112.1 million, and upgrading its FY26 full-year revenue guidance from low double-digit to mid double-digit percentage growth — tracking toward the company's NZ$2 billion medium-term sales ambition a full year ahead of plan.
  • Infant Milk Formula (IMF) revenue grew 13.6% year-on-year in 1H26, with English label IMF growing 20.9% and China label IMF growing 6.5% while achieving record market share in China — reinforcing the company's core growth narrative even as the broader infant formula market faces demographic headwinds.
  • Underlying EBITDA grew 25.9% and underlying NPAT grew 19.6% — materially ahead of the reported figures — reflecting the drag from a2 Pokeno losses of NZ$9.8 million EBITDA and NZ$10.4 million NPAT in the half, as the acquired processing facility operates at temporarily low volumes ahead of the a2 Platinum transition scheduled for 1H27.

The a2 Milk Company's (ASX:A2M) 1H26 results, released on February 16, 2026, presented investors with a compelling combination: revenue up 18.8%, EBITDA up 18.4%, a full-year guidance upgrade, and the declaration that the company is on track to achieve its NZ$2 billion medium-term revenue target a full year ahead of the original plan. By conventional metrics of consumer-sector performance, this is the profile of a company in strong operational stride.

On April 1, 2026, A2M shares declined 2.717% to A$9.31 in a session where the broader market was rising. This disconnect between reported performance quality and share price reaction reflects several dynamics that are worth examining carefully: the impact of transformation-related costs at the a2 Pokeno facility on reported earnings, residual investor uncertainty about the trajectory of China IMF market dynamics, the translation effects between New Zealand dollar results and Australian dollar share price performance, and the market's tendency to discount forward guidance upgrades that are accompanied by near-term earnings drags.

Revenue Growth Across All Segments: A Genuine Broad-Based Performance

The a2 Milk Company's 1H26 revenue growth of 18.8% to NZ$993.5 million was notably broad-based — not concentrated in a single geography or product category but distributed across all segments and most major product lines. China and Other Asia segment revenue grew 20.3%, ANZ grew 8.6%, and the USA grew 29.0%. This geographic diversification of growth is significant because it reduces the concentration risk that characterised a2 Milk in its earlier periods, when Chinese IMF revenue growth was the dominant — and at times volatile — driver of the overall business.

Within the product mix, Infant Milk Formula remains the largest and most strategically important category. IMF revenue grew 13.6% year-on-year in 1H26, with English label products — sold in Western markets and exported to China — growing 20.9%, supported by growing contribution from the a2 Genesis product range and new market entries. China label IMF grew a more modest 6.5%, but achieved record market share in China during the period — a metric that management regards as more important than short-term volume growth because market share gains represent durable competitive positioning.

The Other Nutritionals category — which includes kids, toddler, and seniors nutrition products — grew 42.9% in 1H26, reflecting the success of recently launched products in these adjacent categories. This growth rate is particularly noteworthy because it demonstrates the company's ability to leverage the a2 brand into categories beyond its core infant formula stronghold. The entry into the Chinese paediatric supplements category — a market estimated at approximately NZ$8 billion in retail sales value — opens a significant new growth platform that management described as a highly attractive adjacency to the core IMF business.

Liquid Milk revenue grew 18.5%, driven by core products alongside lactose-free and grassfed innovations. Both the Australian and US liquid milk businesses achieved double-digit revenue growth, with the US performance in particular (part of the 29% US segment revenue growth) reflecting the deepening penetration of a2 branded milk in the American market, where consumer awareness of the a2 protein benefit has been growing steadily.

The Pokeno Effect: Understanding the Underlying vs. Reported Gap

The gap between a2 Milk's reported financial metrics and its underlying financial metrics in 1H26 is substantial, and understanding this gap is essential to a correct interpretation of the results. Underlying EBITDA grew 25.9% — materially ahead of the 18.4% growth in reported EBITDA. Underlying NPAT grew 19.6% — compared to 9.4% growth in reported NPAT. These differences reflect the decision to exclude the losses from a2 Pokeno, the New Zealand-based processing facility acquired during 1H26.

The a2 Pokeno facility is a strategic acquisition that gives a2 Milk direct ownership of a key part of its dairy supply chain. However, in the immediate post-acquisition period, the facility is operating at temporarily low production volumes while it undergoes the technical and commercial transition required to begin producing a2 Platinum branded products — the company's flagship infant formula product — through Pokeno. This transition is scheduled for completion in 1H27, at which point Pokeno's production volumes and financial contribution are expected to normalise.

In 1H26, a2 Pokeno contributed a reported EBITDA loss of NZ$9.8 million and an NPAT loss of NZ$10.4 million. These losses are temporal in nature — they represent the cost of running a facility through a transition period — rather than a reflection of any underlying operational problem with the Pokeno asset or its long-term earnings capacity. Management has chosen to present underlying figures that exclude these Pokeno losses to provide investors with visibility into the performance of the established business, while being transparent about the acquisition impact in the reported figures.

China IMF: Record Market Share in a Structurally Challenged Market

The China infant formula market is, simultaneously, a2 Milk's largest and most important end market and one of the most structurally challenged consumer markets in the world. China's declining birth rate — a function of decades of demographic policy and shifting social preferences — has been reducing the total size of the infant formula market in China. Against this background, any company that achieves revenue growth and record market share is demonstrating the strength of its competitive positioning rather than simply riding overall market growth.

In 1H26, a2 Milk's China label IMF revenue grew 6.5% while achieving record market share. This combination — growth in absolute revenue alongside market share gains in a declining-volume market — is the strongest possible outcome in the context of Chinese infant formula market dynamics. It means a2 Milk is taking share from competitors at a rate that more than offsets any volume headwind from overall market contraction.

A further strategic development in the China market is the progression of the China label registration amendment process, which management described as on track. The specifics of this regulatory process relate to China's updated requirements for infant formula product registration and label compliance, an area that has been a source of market uncertainty for companies operating in the China IMF space. Progress toward completion of this process removes a potential operational risk and clears the way for the company's Chinese label products to continue selling under regulatory-compliant conditions.

The launch of a new China label paediatric supplements range — entering a market of approximately NZ$8 billion in retail sales value — represents the most significant new product category extension announced in the 1H26 period. The Chinese paediatric supplements market encompasses a range of health and nutritional products for children beyond the infant stage, a category that is adjacent to IMF in both consumer profile and brand relevance. a2 Milk's entry into this category leverages its existing brand equity and China channel relationships while opening a substantially larger addressable market.

Supply Chain Transformation: Pokeno, Fonterra, and the Mataura Valley Divestment

The 1H26 period was one of significant strategic activity in a2 Milk's supply chain architecture. Three major transactions reshaped the company's production and sourcing structure: the completion of the a2 Pokeno acquisition (bringing a New Zealand processing facility into a2 Milk's direct ownership), the divestment of the Mataura Valley Milk business, and the execution of a long-term milk supply agreement with Fonterra.

The combination of these transactions — acquiring Pokeno while divesting Mataura Valley Milk and locking in a Fonterra supply agreement — reflects a deliberate strategic choice to concentrate the company's supply chain investment in a single, strategically owned processing facility (Pokeno) while simplifying and de-risking the upstream milk supply arrangements through the long-term Fonterra relationship. Management described this structure as enabling a2 Milk to build a higher-growth, more profitable and lower-risk end-to-end business over time.

The upgrading of FY26 full-year guidance — from low double-digit percentage revenue growth to mid double-digit percentage growth with improved EBITDA margin range — reflects management's confidence that the 1H26 momentum is sustainable through the second half of the financial year. The guidance upgrade is also effectively a declaration that the company will achieve the NZ$2 billion medium-term sales ambition in FY26 — a milestone that was originally targeted for FY27.

Financial Position: NZ$896.9 Million Cash, No Debt

a2 Milk's balance sheet remains one of the strongest in the ASX consumer sector. Closing cash at December 31, 2025 was NZ$896.9 million, with operating cash conversion of 90.8%. This level of cash holding — in a company with no significant debt — provides exceptional financial flexibility for product development, market expansion, supply chain investment, and shareholder returns.

The declaration of an interim dividend of 11.5 cents per share (unimputed and fully franked) at approximately 74% of NPAT payout demonstrates the Board's willingness to distribute capital to shareholders rather than allow cash to accumulate beyond operational requirements. This payout rate is at the higher end of the company's policy range, signalling confidence in the robustness of near-term cash generation.

Conclusion

The a2 Milk Company's 2.717% share price decline on April 1, 2026 appears inconsistent with the fundamental quality of its 1H26 results. Revenue growth of 18.8%, guidance upgraded to mid double-digit percentage growth, record IMF market share in China, 42.9% growth in Other Nutritionals, and a NZ$2 billion sales milestone being achieved a year ahead of plan collectively represent a consumer growth story of genuine quality. The market's reluctance to reward this performance may reflect: residual uncertainty about the Pokeno transition costs and timeline, scepticism about the China IMF market's medium-term volume trajectory, and the translation effects between NZ dollar results and the AUD-priced shares. For investors focused on the long-term trajectory of the a2 brand, the underlying metrics of 25.9% EBITDA growth and 19.6% NPAT growth — excluding the temporary Pokeno drag — may provide a more informative picture of the business's current momentum.